Administering the HPV Vaccine to People Living with HIV: Providers' Perspectives
Name:
HPV_Vaccine_Koskan_2020.pdf
Size:
289.8Kb
Format:
PDF
Description:
Final Accepted Manuscript
Affiliation
Univ Arizona, Mel & Enid Zuckerman Coll Publ HlthIssue Date
2020-08Keywords
anal cancerHIV/AIDS
Healthcare Practitioners
Human papillomavirus (HPV)
Qualitative research
vaccination
Metadata
Show full item recordPublisher
SPRINGERCitation
Koskan, A., Brennhofer, S.A. & Helitzer, D. Administering the HPV Vaccine to People Living with HIV: Providers’ Perspectives. J Primary Prevent 41, 349–362 (2020). https://doi.org/10.1007/s10935-020-00598-wJournal
JOURNAL OF PRIMARY PREVENTIONRights
© Springer Science+Business Media, LLC, part of Springer Nature 2020.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
HIV-positive patients suffer disproportionate burden of anal cancer, a disease which is primarily caused by persistent infection with human papillomavirus (HPV) and is potentially preventable with the completion of the HPV vaccine series. Past research qualitatively explored HIV-positive patients' perspectives about the HPV vaccine. However, little is known about their healthcare practitioners' vaccine recommendation behaviors, the strongest influence on vaccine uptake. This study reports on in-depth interviews conducted with 25 healthcare practitioners who provide care for HIV-positive patients. Qualitative themes that emerged from the study included clinicians' HPV vaccination behaviors, HIV patient's willingness to get the HPV vaccine, the role of HIV-positive patients' immune functioning in terms of timing of HPV vaccine administration, and vaccinating HIV-positive patients over age 26. The majority of providers offered the vaccine at their healthcare facility. Participants varied in their opinions related to the importance of patients' CD4 count in terms of timing of HPV vaccine administration; some believed that patients' immune functioning should first be stabilized to receive the most benefit from the vaccine series. They also differed in the perceived benefit of offering the vaccine to patients over age 26. In light of the U.S. Food and Drug Administration's recent approval to extend HPV vaccination to adults up to age 45 years, more HIV-positive adults may benefit by receiving this vaccine series. Future efforts should ensure that providers regularly promote the HPV vaccine to their adult HIV-positive patients. Vaccinating HIV-positive patients may help reduce the burden of HPV-related cancers, particularly anal cancer.Note
12 month embargo; published online: 1 July 2020ISSN
0278-095XEISSN
1573-6547PubMed ID
32613520Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1007/s10935-020-00598-w
Scopus Count
Collections
Related articles
- Implementation of a Postpartum HPV Vaccination Program in a Southeast Texas Hospital: A Qualitative Study Evaluating Health Care Provider Acceptance.
- Authors: Gross TT, Rahman M, M Wright A, M Hirth J, Sarpong KO, Rupp RE, D Barrett A, Berenson AB
- Issue date: 2016 Nov
- Health care providers' perspectives on low HPV vaccine uptake and adherence in Appalachian Kentucky.
- Authors: Head KJ, Vanderpool RC, Mills LA
- Issue date: 2013 Jul
- Anal Cancer Prevention Perspectives Among Foreign-Born Latino HIV-Infected Gay and Bisexual Men.
- Authors: Koskan AM, Fernandez-Pineda M
- Issue date: 2018 Jan-Mar
- A model of health care provider decision making about HPV vaccination in adolescent males.
- Authors: Alexander AB, Best C, Stupiansky N, Zimet GD
- Issue date: 2015 Aug 7
- Parents' and providers' attitudes toward school-located provision and school-entry requirements for HPV vaccines.
- Authors: Vercruysse J, Chigurupati NL, Fung L, Apte G, Pierre-Joseph N, Perkins RB
- Issue date: 2016 Jun 2